Literature DB >> 24725632

Symptom dimensional approach and BDNF in unmedicated obsessive-compulsive patients: an exploratory study.

Igor Marcanti Dos Santos, Leandro Ciulla, Daniela Braga, Keila Maria Ceresér, Clarissa Severino Gama, Flávio Kapczinski, Ygor Arzeno Ferrão.   

Abstract

UNLABELLED: IntroductionThe dimensional approach of the obsessive-compulsive symptoms may help to find more homogeneous groups of patients. The brain derived neurotrophic factor (BDNF) may help to identify neurobiological differences between obsessive-compulsive symptom dimensions.
METHODS: We compared serum BDNF (pg/μg) levels of 25 unmedicated patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for obsessivecompulsive disorder (OCD) and 25 controls, using the Dimensional Yale-Brown Obsessive-Compulsive Scale, the Yale-Brown Obsessive-Compulsive Scale and the Beck's Anxiety and Depression Inventories.
RESULTS: There were no sociodemographic differences between the groups. The standard error of mean serum BDNF levels were reduced in unmedicated OCD patients (0.47+0.038) when compared to healthy controls (0.75+0.060) (P<.001). The patients with the presence of sex/religion obsessive-compulsive symptoms (OCS) dimension (P=.002), with chronic course of OCS (P=.022) and the presence of lifetime major depression (P=.016) and social anxiety (P=.030) presented higher levels of BDNF than OCD patients without those features. The severity of aggression (P=.039) and sex/religion (P<.001) OCS dimension presented direct (moderate and strong, respectively) correlation with serum BDNF levels in this sample. Serum BDNF levels were decreased in OCD patients when compared to healthy controls.Discussion/ConclusionSexual and religious content of symptoms and aggression and sex/religion dimensions severity should be better explored, since these specific OCS dimensions could be based on neurocircuits diverse from those of the other OCS dimensions.

Entities:  

Year:  2011        PMID: 24725632     DOI: 10.1017/S1092852912000363

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  2 in total

1.  Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis.

Authors:  Sharain Suliman; Sian M J Hemmings; Soraya Seedat
Journal:  Front Integr Neurosci       Date:  2013-07-29

2.  No association between BDNF Val66Met polymorphism and treatment response in obsessive-compulsive disorder in the Japanese population.

Authors:  Hidehiro Umehara; Shusuke Numata; Makoto Kinoshita; Shinya Watanabe; Shutaro Nakaaki; Satsuki Sumitani; Tetsuro Ohmori
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-11       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.